Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer.
BACKGROUND:Advanced prostate cancers that are resistant to all current therapies create a need for new therapeutic strategies. One recent innovative approach to cancer therapy is the simultaneous use of multiple FDA-approved drugs to target multiple pathways. A challenge for this approach is caused...
Main Authors: | Bao Le, Ginny L Powers, Yu Tong Tam, Nicholas Schumacher, Rita L Malinowski, Laura Steinke, Glen Kwon, Paul C Marker |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5370140?pdf=render |
Similar Items
-
HSP90B1 regulates autophagy via PI3K/AKT/mTOR signaling, mediating HNSC biological behaviors
by: Chao Li, et al.
Published: (2024-04-01) -
PI3K/AKT/mTOR pathway in Angiogenesis
by: Jayashree eKarar, et al.
Published: (2011-12-01) -
Targeting PI3K/Akt/mTOR Signaling In Cancer
by: Camillo ePorta, et al.
Published: (2014-04-01) -
PI3K/Akt/mTOR inhibitors in breast cancer
by: Joycelyn JX Lee, et al.
Published: (2015-12-01) -
Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
by: Carla L. Alves, et al.
Published: (2023-02-01)